Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1/PD-L1 Inhibitors
Latest Information Update: 05 Sep 2022
At a glance
- Drugs Metformin (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Proof of concept; Therapeutic Use
- 20 Sep 2020 Planned End Date changed from 1 Feb 2021 to 1 Sep 2021.
- 20 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 15 Oct 2017 Status changed from not yet recruiting to recruiting, according to trial design presented at 18th World Conference on Lung Cancer.